Related Experiment Videos
Lipids, lipoproteins, and coronary heart disease: implications for antihypertensive therapy
1Department of Therapeutics, Charing Cross and Westminster Medical School, St. Stephen's Hospital, London, U.K.
Insights
Treating abnormal lipids and lipoproteins significantly reduces coronary heart disease (CHD) incidence. However, hypertension treatment
Area of Science:
- Cardiovascular Medicine
- Lipidology
- Pharmacology
Background:
- Lipid and lipoprotein abnormalities are linked to coronary heart disease (CHD).
- Hypertension treatment's impact on CHD is less clear than lipid management.
- Concurrent cardiovascular risk factors or adverse drug effects may explain this discrepancy.
Purpose of the Study:
- To review the relationship between lipids, lipoproteins, and CHD.
- To evaluate the impact of cholesterol lowering on CHD incidence.
- To assess evidence linking antihypertensive drugs to lipid and lipoprotein abnormalities.
Main Methods:
- Literature review of studies on lipids, lipoproteins, and CHD.
- Critical appraisal of research investigating antihypertensive drug effects on lipid profiles.
- Analysis of clinical trial data regarding cholesterol-lowering therapies.
Main Results:
- Strong evidence supports lipid-lowering therapy's benefit in reducing CHD.
- Hypertension treatment's effect on CHD is less consistently demonstrated.
- Some antihypertensive medications may negatively affect lipid and lipoprotein levels, potentially offsetting blood pressure benefits.
Conclusions:
- Lipid management is a proven strategy for CHD prevention.
- The impact of hypertension therapy on CHD requires careful consideration of its effects on lipid profiles.
- Further research is needed to optimize treatment strategies for hypertensive patients with dyslipidemia to maximize cardiovascular risk reduction.
Abstract:
There is now considerable evidence that treatment of abnormalities of lipids and lipoproteins reduces the incidence of coronary heart disease (CHD). Treatment of hypertension, another major cardiovascular risk factor, has not been shown to have the same impact on CHD. Possible explanations for this are that cardiovascular risk factors may occur in combination in an individual or that therapy for hypertension has adversely affected one or several of the other risk factors for CHD, thereby offsetting the benefit gained by lowering blood pressure. This article reviews the relationship between lipids, lipoproteins, and coronary heart disease, and the impact of cholesterol lowering on CHD. The evidence that antihypertensive drugs are associated with lipid and lipoprotein abnormalities is introduced by a critical appraisal of the several studies for such evidence. Implications for the treatment of the hypertensive patient are discussed.